SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001790340-24-000022
Filing Date
2024-03-01
Accepted
2024-03-01 07:58:59
Documents
16
Period of Report
2024-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K imrx-20240301.htm   iXBRL 8-K 24732
2 EX-99.1 imrx-20240229xexx991.htm EX-99.1 112252
6 imlogoa.jpg GRAPHIC 6512
  Complete submission text file 0001790340-24-000022.txt   292788

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT imrx-20240301.xsd EX-101.SCH 1926
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT imrx-20240301_lab.xml EX-101.LAB 26155
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT imrx-20240301_pre.xml EX-101.PRE 13601
17 EXTRACTED XBRL INSTANCE DOCUMENT imrx-20240301_htm.xml XML 2922
Mailing Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142
Business Address 245 MAIN STREET, SECOND FLOOR CAMBRIDGE MA 02142 617-500-8080
Immuneering Corp (Filer) CIK: 0001790340 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40675 | Film No.: 24707008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)